A5074477451- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Systemic Lupus Erythematosus Research
- Functional Brain Connectivity Studies
- Medical Imaging Techniques and Applications
- Advanced Neuroimaging Techniques and Applications
- Inflammatory Myopathies and Dermatomyositis
- S100 Proteins and Annexins
- Systemic Sclerosis and Related Diseases
- Renal Diseases and Glomerulopathies
- Atherosclerosis and Cardiovascular Diseases
- Monoclonal and Polyclonal Antibodies Research
- Neurological Disease Mechanisms and Treatments
- Skin Diseases and Diabetes
- Health, Environment, Cognitive Aging
- Neuroinflammation and Neurodegeneration Mechanisms
- Tryptophan and brain disorders
- Parkinson's Disease Mechanisms and Treatments
- Cerebrovascular and Carotid Artery Diseases
- Neurobiology of Language and Bilingualism
- Neurological and metabolic disorders
- Advanced MRI Techniques and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Traumatic Brain Injury and Neurovascular Disturbances
- Neural dynamics and brain function
Eli Lilly (United States)
2022-2025
Eli Lilly (Italy)
2025
University of California, San Francisco
2016-2024
University Memory and Aging Center
2018-2024
University of Padua
2013-2024
Pakistan Institute of Medical Sciences
2023
University of Pennsylvania
2023
Lund University
2022
Skåne University Hospital
2022
Amsterdam Neuroscience
2022
Tau imaging with [ 18 F]flortaucipir predicts the severity and topography of subsequent MRI cortical atrophy in patients Alzheimer’s disease.
Tau positron emission tomography (PET) tracers have proven useful for the differential diagnosis of dementia, but their utility predicting cognitive change is unclear.To examine prognostic accuracy baseline fluorine 18 (18F)-flortaucipir and [18F]RO948 (tau) PET in individuals across Alzheimer disease (AD) clinical spectrum to perform a head-to-head comparison against established magnetic resonance imaging (MRI) amyloid markers.This study collected data from 8 cohorts South Korea, Sweden, US...
To determine how fully automated Elecsys CSF immunoassays for β-amyloid (Aβ) and tau biomarkers an ultrasensitive Simoa assay neurofilament light chain (NFL) correlate with neuropathologic changes of Alzheimer disease (AD) frontotemporal lobar degeneration (FTLD).We studied 101 patients antemortem neuropathology data. samples were collected a mean 2.9 years before death (range 0.2-7.5 years). was analyzed Aβ40, Aβ42, total (T-tau), phosphorylated at amino acid residue 181 (P-tau), P-tau/Aβ42...
Neuronal- and circuit-level abnormalities of excitation inhibition are shown to be associated with tau amyloid-beta (Aβ) in preclinical models Alzheimer's disease (AD). These relationships remain poorly understood patients AD.Using empirical spectra from magnetoencephalography computational modeling (neural mass model), we examined excitatory inhibitory parameters neuronal subpopulations investigated their specific associations regional Aβ, measured by positron emission tomography,...
Abstract Background Maximizing the efficiency to screen amyloid-positive individuals in asymptomatic and non-demented aged population using blood-based biomarkers is essential for future success of clinical trials early stage Alzheimer’s disease (AD). In this study, we elucidate utility combination plasma amyloid-β (Aβ)-related tau phosphorylated at threonine 217 (p-tau217) predict abnormal Aβ-positron emission tomography (PET) preclinical prodromal AD. Methods We designed cross-sectional...
Abstract Purpose As dual-phase amyloid-PET can evaluate amyloid (A) and neurodegeneration (N) with a single tracer injection, tau-PET might be able to provide both tau (T) N. Our study aims assess the association of early-phase scans 18 F-fluorodeoxyglucose (FDG) PET their comparability in discriminating Alzheimer’s disease (AD) patients differentiating neurodegenerative patterns. Methods 58 subjects evaluated at Geneva Memory Center underwent F-Flortaucipir-PET acquisition (eTAU) F-FDG-PET...
The relationships between β-amyloid (Aβ), tau and neurodegeneration within Alzheimer's Disease pathogenesis are not fully understood. To explore these associations in vivo, we evaluated 30 Aβ PET-positive patients (mean ± sd age 62.4 8.3) with mild probable AD 12 PET-negative healthy controls (HC) 77.3 6.9) as comparison. All participants underwent 3 T MRI, 11C-PiB (Aβ) PET 18F-AV1451 (tau) PET. Multimodal correlation analyses were run at both voxel- region-of-interest levels. retention...
Few studies have evaluated the relationship between in vivo18F-flortaucipir PET and post-mortem pathology. We sought to compare antemortem 18F-flortaucipir neuropathology a consecutive series of patients with broad spectrum neurodegenerative conditions. Twenty were included [mean age at 61 years (range 34-76); eight female; median PET-to-autopsy interval 30 months 4-59 months)]. Eight had primary Alzheimer's disease pathology, nine non-Alzheimer tauopathies (progressive supranuclear palsy,...
The ability to predict the pathology underlying different neurodegenerative syndromes is of critical importance owing advent molecule-specific therapies.To determine rates positron emission tomography (PET) amyloid positivity in main clinical variants primary progressive aphasia (PPA).This prospective clinical-pathologic case series was conducted at a tertiary research clinic specialized cognitive disorders. Patients were evaluated as part prospective, longitudinal study between January 2002...
<h3>Objective</h3> To assess whether Alzheimer disease (AD) clinical presentation and <i>APOE4</i> relate to the burden topography of β-amyloid (Aβ) tau pathologies using in vivo PET imaging. <h3>Methods</h3> We studied 119 Aβ-positive symptomatic patients aged 48–95 years, including 29 with logopenic variant primary progressive aphasia (lvPPA) 21 posterior cortical atrophy (PCA). Pittsburgh compound B (PiB)–Aβ flortaucipir (tau)–PET standardized uptake value ratio (SUVR) images were...
Abstract Background Early-onset Alzheimer’s disease (EOAD) is characterized by young age of onset (< 65 years), severe neurodegeneration, and rapid progression, thus differing significantly from typical late-onset disease. Growing evidence suggests a primary role neuroinflammation in AD pathogenesis. However, the microglia activation EOAD remains poorly explored field. Investigating microglial its influence on development synaptic dysfunction neuronal loss may contribute to understanding...
Alpha and delta-theta brain oscillation deficits depict diverse associations with amyloid TAU accumulations cognitive decline in AD.
<h3>Importance</h3> Amyloid-β (Aβ) deposition is a feature of Alzheimer disease (AD) and may be promoted by exogenous factors, such as ambient air quality. <h3>Objective</h3> To examine the association between likelihood amyloid positron emission tomography (PET) scan positivity quality in individuals with cognitive impairment. <h3>Design, Setting, Participants</h3> This cross-sectional study used data from Imaging Dementia—Evidence for Amyloid Scanning Study, which included more than 18 000...
[18F]FDG-PET hypometabolism patterns are indicative of different neurodegenerative conditions, even from the earliest disease phase. This makes a valuable tool in diagnostic workup diseases. The utility dementia with Lewy bodies (DLB) needs further validation by considering large samples patients and comparisons applying state-of-the-art statistical methods. Here, we aimed to provide an extensive metabolic signatures supporting DLB diagnosis near first clinical assessment, which is...
According to the network model of neurodegeneration, spread pathogenic proteins occurs selectively along connected brain regions. We tested in vivo whether distribution filamentous tau (measured with [18F]flortaucipir-PET), fibrillar amyloid-β ([11C]PIB-PET) and glucose hypometabolism ([18F]FDG-PET) follows intrinsic functional organization healthy brain. included 63 patients Alzheimer's disease (AD; 30 male, ± 8 years) who underwent [18F]flortaucipir, [11C]PIB [18F]FDG PET, 1000 young...
Abstract Posterior cortical hypometabolism measured with 18F-fluorodeoxyglucose (FDG)-PET is a well-known marker of Alzheimer’s disease-related neurodegeneration, but its associations underlying neuropathological processes are unclear. We assessed cross-sectionally the relative contributions three potential mechanisms causing in retrosplenial and inferior parietal cortices: local molecular (amyloid tau) pathology atrophy, distant factors including from degenerating medial temporal lobe or...
Abstract Patients with early‐onset Alzheimer's disease (EOAD) are commonly excluded from large‐scale observational and therapeutic studies due to their young age, atypical presentation, or absence of pathogenic mutations. The goals the Longitudinal EOAD Study (LEADS) (1) define clinical, imaging, fluid biomarker characteristics EOAD; (2) develop sensitive cognitive measures for future clinical research use; (3) establish a trial‐ready network. LEADS will follow 400 amyloid beta (Aβ)‐positive...
Abstract Early-onset (age &lt; 65) Alzheimer’s disease is associated with greater non-amnestic cognitive symptoms and neuropathological burden than late-onset disease. It not fully understood whether these groups also differ in the associations between molecular pathology, neurodegeneration performance. We studied amyloid-positive patients early-onset (n = 60, mean age 58 ± 4, MMSE 21 6, 58% female) 53, 74 23 5, 45% who underwent neurological evaluation, neuropsychological testing,...